However, there are studies highlighting that AML patients with MRG and NPM1 mutations should be classified as intermediate-risk individuals, not as favorable-risk individuals, due to the negative impact of MRGs in the prognosis of NPM1-mutated patients [100]. This evidence concerns the gene NPM1 and acute myeloid leukemia.